StockNews.com Initiates Coverage on Agile Therapeutics (NASDAQ:AGRX)

Investment analysts at StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued to investors on Thursday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Shares of Agile Therapeutics stock opened at $1.51 on Thursday. Agile Therapeutics has a 1 year low of $0.20 and a 1 year high of $2.63. The company has a market capitalization of $10.35 million, a P/E ratio of -0.41 and a beta of 1.58. The business has a 50 day moving average price of $1.48 and a 200 day moving average price of $0.88.

Agile Therapeutics (NASDAQ:AGRX) last issued its quarterly earnings data on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $5.58 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC raised its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.